



Drug Therapy Protocols: Box jellyfish antivenom

Policy code	DTP_BJA_0924
Date	September, 2024
Purpose	To ensure a consistent procedural approach to box jellyfish antivenom administration.
Scope	Applies to Queensland Ambulance Service (QAS) clinical staff.
Health care setting	Pre-hospital assessment and treatment.
Population	Applies to all ages unless stated otherwise.
Source of funding	Internal – 100%
Author	Clinical Quality & Patient Safety Unit, QAS
Review date	September, 2026
Information security	UNCLASSIFIED – Queensland Government Information Security Classification Framework.
URL	https://ambulance.qld.gov.au/clinical.html

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by appropriately qualified QAS clinicians when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

© State of Queensland (Queensland Ambulance Service) 2024.



This work is licensed under the **Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License**

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

For copyright permissions beyond the scope of this license please contact: Clinical.Guidelines@ambulance.qld.gov.au

Box jellyfish antivenom

September, 2024

Drug class^[1,2]

Antivenom

Pharmacology

Box jellyfish antivenom contains concentrated immunoglobulin that acts to neutralise the toxins present in the venom of the box jellyfish (*Chironex fleckeri*).^[1-2]

Metabolism

Hepatic and in muscle tissue.^[1]

Indications^[2-4]

- **Box jellyfish (*Chironex fleckeri*) envenomation** associated with any of the following:
 - a patient currently in cardiac arrest
 - decreased level of consciousness
 - cardiac AND/OR respiratory distress or collapse
 - total surface area affected greater than half the surface area of one limb
 - intractable pain unrelieved by icepacks, methoxyflurane AND/OR narcotic analgesia.

Contraindications

- Allergy AND/OR Adverse Drug Reaction

Precautions^[3]

- The antivenom is a foreign protein, which can cause sensitisation, allergic reaction or anaphylaxis

Side effects^[1,2,4]

- Allergic reaction including anaphylaxis and delayed serum sickness
- Intense stinging sensation on injection

Presentation

- Ampoule, 20,000 units/1.5 – 4 mL *box jellyfish antivenom* (**note:** product has variable volume between batches as it is manufactured to ensure a consistent potency)

Onset (IV)

Not available

Duration (IV)

Not available

Half-life

Not available

Schedule

- S₄ (Restricted drugs).

Routes of administration

Intravenous injection (IV)



Intraosseous injection (IO)



Special notes

- Ambulance officers must only administer medications for the listed indications and dosing range. Any consideration for treatment outside the listed scope of practice requires mandatory approval via the *QAS Clinical Consultation and Advice Line*.
- Box jellyfish antivenom must be available at all coastal QAS stations from Rainbow Beach and north.
- The dose of antivenom is related to the dose of venom, not based on the size of the patient.^[1]

Special notes (cont.)

- At all times during antivenom therapy adrenaline (epinephrine) must be available in case of an anaphylactic reaction. If reaction occurs, immediately cease the administration of box jellyfish antivenom and treat patient in accordance with *CPG: Anaphylaxis and allergy*.
- If a patient is in cardiac arrest due to box jellyfish envenomation, the box jellyfish antivenom is only to be administered following the commencement of effective CPR, advanced life support measures and administration of cardioactive drugs.
- Box jellyfish antivenom must be protected from light and stored between 2–8°C. DO NOT FREEZE.^[1,2]
- Box jellyfish antivenom is delivered directly from the manufacturer (Seqirus®) to station. An officer must be contactable when expecting a delivery of box jellyfish antivenom to ensure timely receipt and to maintain cold chain requirement.

Adult/Paediatric dosages^[1-4]

Box jellyfish (*Chironex fleckeri*) envenomation associated with any of the following:

- Decreased level of consciousness
- Cardiac AND/OR respiratory distress or collapse
- Total surface area affected greater than half the surface area of one limb
- Intractable pain unrelieved by icepacks, methoxyflurane AND/OR narcotic analgesia



IV

20,000 units
 Infusion over 20 minutes.
 Administer via *SPRINGFUSOR*® 30 mL.
Single dose only.
*Syringe preparation: Mix 20,000 units of antivenom with sodium chloride 0.9% in a 30 mL *SPRINGFUSOR*® syringe to achieve a final concentration of 20,000 units/20 mL. Administer via *SPRINGFUSOR*® at a rate of 60 mL/hour (over 20 minutes).*

Adult/Paediatric dosages

Box jellyfish (*Chironex fleckeri*) envenomation associated with a patient currently in cardiac arrest



IV

20,000 units
 Slow push over 2–5 minutes.
Repeated immediately for a further two doses. Total maximum dose 60,000 units.



IO

20,000 units
 Slow push over 2–5 minutes.
Repeated immediately for a further two doses. Total maximum dose 60,000 units.